comprehensive -WSS

comprehensive

author：focus 2025-09-27 09:47:07 - browse：194

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Syphilis numbers in the United States reach record heights

WSS

10 reasons why health care startups fail

At JPM 2024, hospital systems pitch financial strength to investors

Why you shouldn’t ask, “What country has the best health care?”

Pancreatic cancer early detection could be helped by AI

Physician assistants need a new name. Here's what it should be

Male doctors called my cancer incurable. A female doctor showed it wasn't

knowledge

comprehensive

explore

Duchenne breakthrough therapy leaves behind pioneering families

Merck, Johnson & Johnson CEOs will testify on high drug prices

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Investment in vaccine development is lagging, report finds

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Arena BioWorks launches in Cambridge to speed drug discovery

Supreme Court strikes down use of affirmative action

Study suggests new cause of Down syndrome: cells linked to aging

knowledge

Life science postdocs should get big pay hike, NIH panel says

Does Paxlovid work in people vaccinated against Covid

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Gene therapy denied for Afghan refugee whose father aided U.S.

Medicare Advantage overpayments discussion gets experts fired up

The Affordable Care Act has saved billions in health care costs

leisure time

explore

focus

leisure time